Key Insights

Highlights

Success Rate

84% trial completion

Research Maturity

59 completed trials (45% of total)

Clinical Risk Assessment

Based on trial outcomes

High Risk

Score: 62/100

Termination Rate

8.5%

11 terminated out of 130 trials

Success Rate

84.3%

-2.3% vs benchmark

Late-Stage Pipeline

4%

5 trials in Phase 3/4

Results Transparency

5%

3 of 59 completed with results

Key Signals

3 with results84% success11 terminated

Data Visualizations

Phase Distribution

94Total
Not Applicable (65)
Early P 1 (3)
P 1 (15)
P 2 (6)
P 3 (1)
P 4 (4)

Trial Status

Completed59
Recruiting27
Unknown19
Terminated11
Not Yet Recruiting9
Enrolling By Invitation3

Trial Success Rate

84.3%

Benchmark: 86.5%

Based on 59 completed trials

Clinical Trials (130)

Showing 20 of 20 trials
NCT01031407Completed

Cognitive Neuroscience of Autism Spectrum Disorders

NCT01175993Phase 1CompletedPrimary

Effects of Rapid-Resisted Exercise and Bright Light Therapy on Ambulatory Adults With Traumatic Brain Injury

NCT06692400Not ApplicableRecruiting

The Effects of Endotracheal Suctioning on Pain and Serum Markers

NCT07678684Phase 2Recruiting

A Study of HF1K16 Combined With Bevacizumab in Patients With Recurrent or Progressive Glioma

NCT07665944Not ApplicableRecruitingPrimary

Hydroponic vs Conventional Spinach Smoothies: Effects on Salivary Nitrate Bioavailability and Blood Pressure

NCT00004577Recruiting

Study of New Magnetic Resonance Imaging Methods of the Brain

NCT07592624Not ApplicableNot Yet Recruiting

Evaluation of an Instructional Video About Medication Management During Admission and Medication Adherence for Kidney Transplantation and in the Outpatient Clinic in a Dutch University Hospital.

NCT07587944Recruiting

Biomarkers in Bone Marrow Supernatant for Predicting AML Chemosensitivity

NCT07582900CompletedPrimary

The Impact of Hunova® Robotic Platform Rehabilitation

NCT06077903Early Phase 1TerminatedPrimary

GT101 Injection in the Treatment of Metastatic/Recurrent Advanced Solid Tumors

NCT06094426Early Phase 1Terminated

Autologous Tumor Infiltrating Lymphocyte Injection for the Treatment of Advanced Solid Tumors

NCT06519669Not ApplicableTerminatedPrimary

Autologous Tumor-Infiltrating Lymphocyte Injection(GT201) for Treatment of Patients With Advanced Lung Cancer

NCT06235242Not ApplicableTerminatedPrimary

GT201 Injection in Combination With Teraplizumab Injection for Treatment of Patients With Non-small Cell Lung Cancer

NCT06191900Not ApplicableTerminatedPrimary

Clinical Study of GT201 in the Treatment of Advanced Gynecological Tumors (Advanced Cervical Cancer)

NCT06241781Phase 2RecruitingPrimary

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients With Recurrent or Metastatic Cervical Cancer

NCT06453057Not ApplicableRecruitingPrimary

Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Solid Tumours

NCT06819293Phase 1Recruiting

IB-T101 Injection for Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma

NCT06819280Not ApplicableRecruitingPrimary

Autologous Tumor-Infiltrating Lymphocyte (GT307) for Treatment of Patients With Advanced Colorectal Cancer

NCT07498881Not ApplicableNot Yet RecruitingPrimary

LasaiON is an Evidence-informed, Multimodal Self-regulation Program Designed to Reduce Emotional Distress and Strengthen Stress-regulation Skills by Combining Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) With Breathing Supported by Heart-rate Variability Biofeedback (HRV-B; emWave).

NCT06867198Not ApplicableRecruiting

Peanuts for Cardiometabolic, Brain, and Intestinal Health

Scroll to load more

Research Network

Activity Timeline